60 DEGREES PHARMA INC (SXTP)
US83006G1040 - Common Stock
In today's session, these stocks are experiencing unusual volume.
Which stocks have an unusual volume on Thursday?
60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital
60 Degrees Pharmaceuticals expands tafenoquine trial for babesiosis to Brigham and Women’s, targeting severe cases with unmet medical needs. ...
Which stocks are moving after the closing bell on Tuesday?
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results
60 Degrees Pharma (SXTP) reported 164% revenue growth and clinical progress on ARAKODA® for infectious diseases and babesiosis in its 3Q24 earnings...
60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch
60 Degrees Pharmaceuticals launches a pilot to boost ARAKODA® awareness, focusing on virtual sales and a co-pay program for malaria prevention....
60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharmaceuticals closes a $4M private placement for working capital and R&D, with stock and warrants priced at $1.38 per share....
60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharmaceuticals raises $4M through private placement for working capital, commercialization, and R&D, with H.C. Wainwright as placement agent....
60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements
60 Degrees Pharmaceuticals regains Nasdaq compliance after achieving a minimum closing bid price of $1.00 for 10 consecutive days....
SXTP Stock Earnings: 60 Degrees Misses EPS, Misses Revenue for Q2 2024
SXTP stock results show that 60 Degrees missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
SXTP Stock Earnings: 60 Degrees Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips 60 Degrees (NASDAQ:SXTP) just reported results for the second quarter of 2024.6...
60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results
60 Degrees Pharma Q2 2024 net product revenues doubled YoY to $125K, with an 18.3% sequential growth. Gross profit rose to $35K from a $124K loss....
Why Is 60 Degrees Pharmaceuticals (SXTP) Stock Up 29% Today?
60 Degrees Pharmaceuticals stock is up on Monday as SXTP investors react to an update on a clinical trial of SJ733.
60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study
60 Degrees Pharma grants U of Kentucky a right of reference to ARAKODA® NDA for a Phase IIb trial combining SJ733 with tafenoquine to treat vivax malaria....
60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split
60 Degrees Pharma (NASDAQ: SXTP) announces a 1-for-12 reverse stock split, effective August 12, 2024 to meet Nasdaq’s $1.00 minimum bid price...
60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support
60 Degrees Pharmaceuticals secures a U.S. Army contract to support ARAKODA® packaging validation, with Q1 2024 sales up 515% year-over-year to $105.7K....
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Pre-market stock movers are a hot topic as we dive into all of the biggest news traders need to know about on Monday morning!
Palo Alto Networks (PANW) Stock Pops as CrowdStrike Outage Boosts Rivals
Palo Alto Networks stock is up on Friday as shares of PANW are getting a boost from a global CrowdStrike outage affecting Windows devices.
60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study
60 Degrees Pharma begins enrolling patients for a tafenoquine babesiosis trial at Yale, Tufts, and Rhode Island Hospital, with results expected Sept.,...
Why Is SunPower (SPWR) Stock Down 10% Today?
SunPower stock is down on Friday as investors in SPWR react to news of the solar power company halting some of its operations on Sept. 17.
Why Is Nauticus Robotics (KITT) Stock Down 19% Today?
Nauticus Robotics stock is down on Friday after the company announced a one-for-36 reverse stock split for KITT shares on Monday.
Why Is 60 Degrees (SXTP) Stock Up 56% Today?
60 Degrees stock is up on Friday with heavy trading of SXTP shares despite a lack of news from the specialty pharmaceutical company.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are a hot topic on Friday as we check out all of the stories affecting shares on the last day of trading this week!
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning!
60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
60 Degrees Pharma wins IRB approval for tafenoquine study for treating persistent babesiosis in immunocompromised patients despite prior treatment....
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
60 Degrees Pharmaceuticals enrolls first patient in a clinical study at Tufts to assess safety and efficacy of tafenoquine in treating acute babesiosis....
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis
60 Degrees Pharmaceuticals receives FDA orphan drug status for tafenoquine to treat acute babesiosis, offering market exclusivity and tax incentives....
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news affecting shares this morning!
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
60 Degrees Pharmaceuticals to start the first clinical trial of tafenoquine for babesiosis at Tufts Medical Center. Enrollment begins June 13, 2024....
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
60 Degrees Pharmaceuticals funds a study at NC State to test for Babesia spp in chronic fatigue patients, aiming to link these infections to CFS...